Biopta

The CHMP (Committee for Medicinal Products for Human Use) has adopted a positive opinion for Galderma's nemolizumab for the treatment of moderate-to-severe atopic dermatitis (AD) and prurigo nodularis (PN) in the EU. Nemolizumab targets IL-31, a key neuroimmune cytokine in the itch-signalling and inflammation pathways, will help patients by tackling one of the most problematic symptoms. This follows its U.S. FDA approval for PN earlier this year. At REPROCELL, we support innovations like these by offering human tissue assays for drug discovery studies. Our assays in fresh skin biopsies can measure critical cytokines like IL-31, providing disease-relevant human data to accelerate drug development. Read more information in the press release here: https://hubs.ly/Q02_V6Jw0

Inflammatory bowel disease (IBD) affects millions worldwide, with prevalence rising sharply. Despite advancements in treatments for Crohn’s disease and ulcerative colitis, the complexity of IBD presents ongoing challenges, including the persistent therapeutic ceiling limiting remission rates. At REPROCELL, we’re addressing this challenge head-on. By leveraging human-derived and bioengineered tissue models, we provide disease-relevant insights that mimic patient responses, enabling researchers to develop innovative, targeted therapies. From evaluating inflammation and fibrosis to testing combination therapies, our cutting-edge models are redefining preclinical research for IBD. Together, we can push past the therapeutic ceiling and improve outcomes for patients. Learn how we’re advancing IBD drug discovery in our new blog: https://hubs.li/Q02_n7_W0

It's beginning to look a lot like Christmas at REPROCELL! 🎄 In addition to wearing our festive jumpers, our team collected non-perishable food items to donate to the local food bank. It was a wonderful way to embrace the holiday season while giving back to the community. We wish you all a merry start to the holiday season. Stay tuned for more information about holiday closures and shipping information.

Looking for a trusted partner in clinical biospecimen research? REPROCELL’s team of human tissue experts specializes in the precise handling, processing, and testing of clinical biospecimens. Our expertise ensures high-quality, human-relevant data to support your drug discovery and development programs. Let us help you drive innovation in your research. Discover how REPROCELL can make a difference: https://hubs.li/Q02_4b_30

Looking to streamline your clinical trial operations? At REPROCELL, our efficient sample processing and analysis services help you save time and resources, ensuring your studies run smoothly and deliver results faster. Discover how we can support your clinical research goals. Learn more today! #ClinicalTrials #Efficiency #DrugDiscovery

As we push towards more translational approaches in drug discovery, human tissue testing is proving to be a transformative innovation. Its ability to closely replicate human physiology and disease states brings us closer to developing therapies that address real patient needs. This shift not only enhances drug development precision but also reinforces the importance of patient-centric research. What excites you most about the potential of human tissue testing? Share your thoughts below.

Artificial Intelligence (AI) is revolutionizing the pharmaceutical industry, especially in clinical trials. From targeted patient selection to streamlined recruitment processes, AI is improving efficiency and delivering better outcomes. Highlights from our new blog: - AI analyzes real-world data, such as electronic health records (EHRs), to identify ideal patient groups. - Digital twins simulate patient responses, advancing personalized medicine. - AI-powered platforms like CURATE .AI dynamically optimize treatment plans, enhancing efficacy and safety. The result? Faster trials, improved success rates, and accelerated drug delivery to the market. Discover how AI is shaping the future of precision medicine and transforming healthcare in our latest blog. https://hubs.li/Q02ZGLWN0

Embarking on the journey of drug development comes with its challenges—but it also offers incredible opportunities. Our comprehensive suite of preclinical human assays is designed to help you de-risk your programs and increase success rates. By leveraging human-relevant models, we: - Deliver disease-relevant insights for better predictions. - Mitigate risk by focusing on data-rich, human-specific assays. - Support smarter decision-making early in the drug development process. Your next breakthrough is closer than you think. REPROCELL can turn your challenges into opportunities and fast-track your journey from discovery to market. Explore how we can support your programs here: https://hubs.ly/Q02ZxHmZ0

One of the most transformative advancements in drug discovery is the use of human tissue testing to validate preclinical drug assets. By leveraging patient-derived living tissues, researchers can establish proof of concept in models that closely mimic human disease. This validation does more than boost scientific confidence—it has a profound impact on the development process, adding significant commercial value by reducing the risk of late-stage failures and supporting data-driven decision-making. At REPROCELL, we are proud to advance drug discovery with data-rich, disease-relevant human tissue studies that help pave the way for safer, more effective therapies. Curious about how this approach can benefit your pipeline? Let’s connect!

Leverage REPROCELL's global reach and expertise to streamline the coordination and execution of your clinical research projects. With a strong international presence and specialized knowledge, we ensure reliable support and seamless operations for advancing your research goals. https://hubs.li/Q02YH0Dd0 #ClinicalResearch #DrugDevelopment